EGFR and non-small cell lung carcinoma: (Figure 6a) displays the finding that supports the assumption that mutagenesis driven by AXL may lead to the emergence of uncommon mutations of EGFR, such as T790M in shLDOC1 EGFRM NSCLC cells, and confers resistance to gefitinib and erlotinib in LDOC1-depleted PC9 cells.